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A B S T R A C T
Hypophosphatasia (HPP) features low tissue-nonspecific alkaline phosphatase (TNSALP) isoenzyme activity
resulting in extracellular accumulation of its substrates including pyridoxal 5′-phosphate (PLP), the principal
circulating form of vitamin B6, and inorganic pyrophosphate (PPi), a potent inhibitor of mineralization. Asfotase
alfa is an enzyme replacement therapy developed to treat HPP. This multinational, randomized, open-label study
(NCT01163149; EudraCT 2010-019850-42) evaluated the efficacy and safety of asfotase alfa in adults and
adolescents 13–66 years of age with HPP. The study comprised a 6-month primary treatment period and a 4.5-
year extension phase. In the primary treatment period, 19 patients were randomized to receive asfotase alfa
0.3mg/kg/d subcutaneously (SC; n= 7), asfotase alfa 0.5mg/kg/d SC (n=6), or no treatment (control; n= 6)
for 6months. In the extension phase, patients received asfotase alfa (0.5 mg/kg/d for 6mo–1 y, then 1mg/kg/d
6 d/wk). During the primary treatment period, changes from Baseline to Month 6 in plasma PLP and PPi con-
centrations (coprimary efficacy measure) were greater in the combined asfotase alfa group compared with the
control group, reaching statistical significance for PLP (P=0.0285) but not for PPi (P=0.0715). However, for
the total cohort, the within subject changes in both PLP and PPi after 6months and over 5 years of treatment
with asfotase alfa were significant (P < 0.05). Secondary efficacy measures included transiliac crest histo-
morphometry, dual-energy X-ray absorptiometry (DXA), and the 6-Minute Walk Test (6MWT). A significant
decrease from Baseline in mineralization lag time was observed in the combined asfotase alfa group at Year 1.
There were no significant differences between treated and control patients in DXA mean bone mineral density
results at 6months; Z-scores and T-scores were within the expected range for age at Baseline and remained so
over 5 years of treatment. On the 6MWT, median (min, max) distance walked increased from 355 (10, 620;
n= 19) meters before treatment to 450 (280, 707; n= 13) meters at 5 years (P < 0.05). Results for the ex-
ploratory outcome measures suggested improvements in gross motor function, muscle strength, and patient-
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reported functional disability over 5 years of treatment. There were no deaths during this study. Asfotase alfa
was generally well tolerated; the most common adverse events were mild to moderate injection site reactions.
This study suggests that in adults and adolescents with pediatric-onset HPP, treatment with asfotase alfa is
associated with normalization of circulating TNSALP substrate levels and improved functional abilities.
1. Introduction
Hypophosphatasia (HPP) is the rare metabolic disease caused by
loss of function mutation(s) of the gene (ALPL) that encodes the tissue-
nonspecific isoenzyme of alkaline phosphatase (TNSALP) [1–3]. In-
heritance of HPP is autosomal recessive or dominant, with>340 mu-
tations identified to date [4,5]. Low TNSALP activity on cell surfaces in
HPP leads to extracellular accumulation of the TNSALP substrates
pyridoxal 5′-phosphate (PLP) [1,6,7], inorganic pyrophosphate (PPi)
[1,8,9], and phosphoethanolamine [1,10]. PPi is an inhibitor of mi-
neralization and its superabundance in HPP can cause rickets in chil-
dren or osteomalacia in adults [1,10,11]. The signs, symptoms, and
sequelae of HPP can present from in utero to adulthood and can vary
widely among patients [11–13]. In the case of adolescents and adults,
the onset of signs and symptoms of HPP may have occurred in infancy
or later in childhood or adulthood [14,15]. HPP in adults commonly
presents with recurring/poorly healing metatarsal fractures, pseudo-
fractures, loss of teeth and sometimes muscle weakness, altered am-
bulation, and bone, joint, and muscle pain [14,16–22]. Some adults
may manifest isolated signs or symptoms, such as tooth loss or ar-
thropathy, without overt bone disease [23].
Asfotase alfa (Alexion Pharmaceuticals, Inc., Boston, MA, USA) is a
human recombinant enzyme replacement therapy developed to treat
HPP [24]. Studies of affected infants and children showed that therapy
with asfotase alfa improved skeletal mineralization and other ab-
normalities, growth, mobility, respiratory function, survival, and pain,
with benefits sustained up to 7 years of therapy [25–28]. The objective
of the current study was to assess the efficacy and safety of asfotase alfa
in adults and adolescents with HPP.
2. Methods
2.1. Study design
This study complied with the World Medical Association
Declaration of Helsinki and the International Conference on
Harmonisation E6 Guideline for Good Clinical Practice. Approval was
obtained from the institutional review board or research ethics board at
each investigative site. All patients or their legal guardians provided
informed consent or assent.
This multicenter, randomized, open-label, Phase 2 study
(NCT01163149) was conducted at 3 sites (2 in the United States and 1
in Canada). It consisted of a 6-month primary treatment period fol-
lowed by an open-label extension phase. In the primary treatment
period, patients were randomized to 1 of 3 groups: asfotase alfa ad-
ministered subcutaneously (SC) at 0.3mg/kg/d (2.1mg/kg/wk) or
0.5 mg/kg/d (3.5mg/kg/wk) or no treatment (control group) (Fig. 1).
During the extension phase all patients initially received asfotase alfa
0.5 mg/kg/d, but after approximately 6months to 1 year the dose was
increased to 1mg/kg/d for 6 d/wk (6mg/kg/wk) under a protocol
amendment; for 1 patient this was not implemented. The change to
6mg/kg/wk was made to match the lowest dose showing efficacy in
children with HPP [27].
2.2. Inclusion and exclusion criteria
Eligibility criteria were age 13–65 years and a pre-established di-
agnosis of HPP based on medical history and findings consistent with
HPP, including subnormal age-adjusted serum alkaline phosphatase
(ALP) activity; high plasma PLP concentration (≥2× upper limit of
normal; no vitamin B6 administered ≥1week before specimen collec-
tion); and osteopenia on skeletal radiographs. Patients must have had
osteomalacia documented by iliac crest biopsy per protocol to partici-
pate in the study. (Additional details are provided in the Supplemental
materials.)
Principal exclusion criteria were subnormal serum calcium or
phosphate concentrations or 25-hydroxyvitamin D concentrations<
20 ng/mL (patients failing initial screening because of low 25-hydro-
xyvitamin D could be rescreened at the discretion of the investigator
after vitamin D supplementation); serum creatinine or parathyroid
hormone (PTH) concentrations above the upper limit of normal; off-
label treatment with a PTH analog within 6months; or use of bispho-
sphonates within 2 years of study entry or for> 2 years at any time.
Patients with prior bisphosphonate use were included only if they had
normal or elevated levels of serum C-telopeptide and urine N-telopep-
tide or deoxypyridinoline.
2.3. Efficacy assessments
2.3.1. Coprimary efficacy measure
The coprimary efficacy measure was change in plasma PLP (ng/mL)
and PPi (μM) concentrations from Baseline to Month 6 in the combined
Fig. 1. Study design.
aAsfotase alfa dose was adjusted for patient body weight every 3months; maximum daily dose was 80mg unless the investigator, after consultation with the medical
monitor, approved a higher dose.
bDose increased by protocol amendment in all patients. During the extension phase, all patients initially received daily doses of asfotase alfa 0.5mg/kg/d for
approximately 6months to 1 year, then increased to 1mg/kg 6 d/wk.
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asfotase alfa treatment group that received either dose of asfotase alfa
(0.3 or 0.5 mg/kg/d) versus the control group (see Supplemental ma-
terials). Vacutainer tubes for this blood sampling contained levamisole
to inhibit the high ALP activity from asfotase alfa.
2.3.2. Secondary efficacy measures
2.3.2.1. Bone mineralization and bone mineral density. Transiliac crest
biopsy was performed at Baseline and Year 1 in the asfotase alfa group
and at Baseline and Month 6 in the control group. Instructions for
preparing and handling the biopsy sample were provided to each site.
Three patients (1 each in the control group, 0.3 mg/kg/d group, and
0.5 mg/kg/d group) who had undergone pretreatment bone biopsy in a
prior Phase 1, dose-escalating, pharmacokinetic study of asfotase alfa
(ENB-001-08/NCT00739505) had their biopsy results used as Baseline
values for the current study. The current Phase 2 study began enrolling
patients approximately 2 years after the 2-month Phase 1 study. To
label the bone for dynamic histomorphometric assessment, patients
received tetracycline for 2 3-day periods separated by approximately
2 weeks; biopsies were performed approximately 21 days after the
second tetracycline dosing period. To ensure consistency across the
asfotase alfa development program, all bone biopsy samples to assess
the histomorphometric changes during the study were also analyzed at
Shriners Hospital for Children, Montreal (Quebec, Canada). Percent of
healthy mean values for bone biopsy parameters were calculated as
observed value/healthy mean× 100, based on reference values
available for males and females 1.5–22.9 years of age [29] and for
postmenopausal women 45–74 years of age [30]. A score of 100%
would indicate no difference from the healthy population.
Dual-energy X-ray absorptiometry (DXA) was performed at Baseline
and every 6months thereafter. Bone mineral density (BMD) Z-scores
were calculated for the lumbar spine, femoral neck (or total hip), and
whole body. A Z-score of −2.0 or lower is considered ‘below the ex-
pected range for age’ [31]. T-scores were calculated for patients older
than 50 years of age. Postmenopausal status was not systematically
captured in the study. The type of DXA machine and software did not
change for each patient. A phantom was not used to calibrate the results
across the study sites.
2.3.2.2. Walking ability. Walking ability was measured using the 6-
Minute Walk Test (6MWT) performed in accordance with American
Thoracic Society guidelines (2002) [32] by a licensed physical therapist
at Screening, Baseline, Month 3, Month 6, and every 6months
thereafter (also performed at Month 9 [3months after initiating
asfotase alfa] in the control group). When possible, the 6MWT was
performed before an injection of asfotase alfa and bone biopsy. The
primary measurement for the 6MWT was distance walked (in meters)
for all patients who attempted the 6MWT (i.e., walking the full 6
minutes was not required). The % predicted value for the 6MWT,
defined as the % of normal predicted distance walked based on age, sex,
and height [33,34], was calculated if the patient walked the full 6
minutes and was ≤65 years of age. Use of ambulatory assistive devices
during the 6MWT was not collected systematically, and was not an
efficacy measure of the study, but was sometimes documented in the
investigator notes during assessment. If a patient was wheelchair
bound, such that they could not participate in the 6MWT, their use of
assistive devices was not collected in this setting. The minimally
clinically important difference (MCID) in 6MWT distance walked for
adults and adolescents with pediatric-onset HPP is 31m and 43m,
respectively [35].
2.3.3. Exploratory efficacy measures
The Bruininks-Oseretsky Test of Motor Proficiency, second edition
(BOT-2), hand-held dynamometry (HHD), Lower Extremity Functional
Scale (LEFS), and Brief Pain Inventory–Short Form (BPI-SF) were ad-
ministered by a licensed physical therapist at Screening, Baseline,
Month 3, Month 6, and every 6months thereafter (also at Month 9
[3months after initiating asfotase alfa] in the control group). When
applicable, these assessments were performed before an asfotase alfa
injection and bone biopsy.
2.3.3.1. Motor function. Gross motor function was evaluated using the
Running Speed and Agility and the Strength subtests of the modified
version of the BOT-2, a validated assessment of motor ability in
individuals 4–21 years of age [36]. Portions of the BOT-2 were
videotaped to assess qualitative changes in gross motor function.
Because study patients were 13–66 years of age (only 6 were
13–21 years of age at enrollment), the BOT-2 total scores, rather than
scaled or age-standardized scores, were reported.
2.3.3.2. Muscle strength. Muscle strength was measured using HHD
[37] of the hip extensors and hip abductors.
2.3.3.3. Patient-reported functional disability. Patient-reported functional
disability was evaluated using the validated LEFS, which is scored 0–80,
with higher scores indicating better functioning [38]. The LEFS assessed
performance of transitional movements (e.g., getting out of bath, rolling
over in bed, getting into or out of a car), locomotion (e.g., walking,
running), climbing stairs, and squatting. The MCID in the LEFS score is 9
points for patients with musculoskeletal dysfunction of the lower
extremities [38].
2.3.3.4. Patient-reported pain. Pain was evaluated using the modified
version of the BPI-SF, a validated questionnaire comprising 4 items that
assess pain severity (0= no pain, 10=worst pain you can imagine)
[39,40]. The total pain severity score (0= no pain to 40=worst pain)
was calculated from the 4 pain severity items.
2.4. Safety and tolerability
Safety assessments included monitoring of any adverse events (AEs)
at each study visit, including injection site reactions (ISRs) and injec-
tion-associated reactions (IARs). ISRs were treatment-related AEs lo-
calized to the site of administration of asfotase alfa that occurred any
time after initiation of asfotase alfa treatment, and IARs were systemic
signs, symptoms, or findings (e.g., generalized urticaria or itching,
hypotension, respiratory distress) that occurred within 3 hours after
asfotase alfa administration. Both ISRs and IARs were assessed by the
investigator as possibly, probably, or definitely related to the study
drug. Additional safety assessments included physical examination
findings, laboratory assessments, and anti–asfotase alfa antibody testing
(PPD Laboratories, Richmond, VA). Serum ALP activity was measured
using a standard CLIA (Chemical Laboratory Improvement
Amendments) chemistry panel assay. All patients underwent renal ul-
trasound and a complete ophthalmic examination at Baseline and every
6months thereafter to assess for ectopic calcification. Occurrences of
fractures were not collected systematically but, if reported, were cap-
tured as an AE.
2.5. Statistical analyses
Efficacy analyses were performed on the full analysis set (FAS),
which included all randomized patients. The safety population included
all patients who received ≥1 dose of asfotase alfa. Group comparisons
were made between the combined asfotase alfa group and the control
group in the primary treatment period. Analyses of within subject
changes in the total cohort after exposure to asfotase alfa were also
carried out to 5 years of treatment. Patients in the asfotase alfa groups
began treatment at the onset of the primary treatment period, whereas
the control group began 6months later at the onset of the extension
phase. Because of the timing of study visits, time points were ap-
proximated, with 48weeks defined as 1 year.
For the coprimary efficacy measures of change in plasma
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concentrations of PLP and PPi from Baseline to Month 6, comparisons
between the combined treatment group and the control group were
made using an exact Wilcoxon rank-sum test for each parameter using a
2-sided alpha of 0.05. Results from this testing were used to determine
if the treated patients had statistically significantly larger changes from
Baseline than the control group. Since 2-sided testing was used, the
statistical superiority of asfotase alfa treatment was established when P
values were< 0.05 and the Hodges-Lehman-Sen estimate of between-
group differences in the change from Baseline favored treatment vs.
control. Missing values at Month 6 were imputed using last observation
carried forward.
Statistical comparisons between the control group and the com-
bined treatment group for bone biopsy results was not performed be-
cause of the difference in timing of the bone biopsies between the 2
groups (Month 6 and Year 1, respectively; see Discussion). However,
the mean within patient change from Baseline and corresponding 95%
confidence intervals (CIs) were calculated; changes were considered
statistically significant (P < 0.05) if the 95% CIs did not include 0
(zero). For other secondary measures, including BMD Z-scores, 6MWT
distance walked, and % predicted distance walked in the primary
treatment period, statistical comparisons between the pooled asfotase
alfa group and the control group were performed using the exact
Wilcoxon rank-sum test and a 2-sided alpha of 0.05; no corrections to
the alpha threshold were made for multiple comparisons. Analyses of
plasma PPi, plasma PLP, BMD Z-scores and T-scores, 6MWT distance
walked, and 6MWT % predicted distance walked were also performed
using pooled data from the primary treatment period and the extension
phase (when all patients received asfotase alfa). The mean change from
Baseline and corresponding 95% confidence intervals (CIs) were cal-
culated for each time point; changes were considered statistically sig-
nificant (P < 0.05) if the 95% CIs did not include 0. Although these
statistical comparisons were performed, the study was not powered to
show differences in these secondary measures. No statistical analyses
were performed for the exploratory efficacy measures of motor func-
tion, muscle strength, disability, and pain.
3. Results
3.1. Patients
Study disposition of patients is summarized in Fig. 2. Of the 22
patients who were screened, 19 were randomized to asfotase alfa
0.3 mg/kg/d (n= 7), asfotase alfa 0.5mg/kg/d (n=6), or control
(n= 6) in the primary treatment period. All patients then received
asfotase alfa in the extension phase as planned. Five patients dis-
continued asfotase alfa treatment before study end. Three of the 5 pa-
tients withdrew consent (asfotase alfa 0.3mg/kg/d group, age:
16 years; asfotase alfa 0.3mg/kg/d group, age: 14 years; control group,
age: 14 years); although AEs were not reported by the investigator as
the cause of discontinuation, all 3 had ongoing mild or moderate ISRs
consisting of injection site atrophy, lipohypertrophy, and/or skin dis-
coloration. A fourth patient (control group, age: 26 years) was dis-
continued because of noncompliance, and a fifth patient (asfotase alfa
0.5 mg/kg/d group, age: 55 years) was discontinued after approxi-
mately 5 years of treatment because of 2 serious AEs (SAEs; injection
site hypersensitivity and anaphylactoid reaction). Thus, a total of 16
patients received asfotase alfa for ≥4 years and 15 patients received
asfotase alfa for ≥5 years.
Patient demographics and Baseline characteristics, including HPP
disease-related history, are summarized in Table 1. The median age at
enrollment was considerably lower in the control group (21.0 years;
range: 13–58 years) than in the combined asfotase alfa group
(55.0 years; range: 14–66 years). Although 1 patient 66 years of age was
enrolled, which was considered a protocol deviation, this deviation was
Fig. 2. Patient disposition.
aThe dose of asfotase alfa was not increased to 1mg/kg 6 d/wk in 1 patient; the dose was reduced to 0.5mg/kg 3 d/wk at ~Year 1 because of multiple injection site
reactions of atrophy, discoloration, and pruritus.
bOne patient discontinued the study because of 2 serious adverse events of injection site hypersensitivity and anaphylactoid reaction after approximately 5 years of
treatment.
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not considered likely to influence treatment effect, and therefore this
patient was included in the analyses. Most patients were white (18/19
[94.7%]), female (12/19 [63.2%]), and adult (≥18 years of age; 13/19
[68.4%]). Ages reported for HPP sign or symptom onset ranged from 0
to 36 years (median: 2.0 years); most patients (14/19 [73.7%]) had
childhood HPP, 4 (21.1%) had infantile HPP, and 1 (5.3%) had adult
HPP. Median ALP activity at Baseline was 23.5 U/L for the control
group and 18 U/L (the lower limit of detection) for the 0.3 and 0.5 mg
groups [10,11]. All patients harbored ALPL mutations: 13 had com-
pound heterozygous mutations, 5 had single copy dominant mutations,
and 1 had a unique splice mutation [4]. The most common ALPL mu-
tations were c.571G > A (8/19 patients [42.1%]), c.526G > A (4/19
[21.1%]), and c.1001G > A (4/19 [21.1%]).
3.2. Efficacy
3.2.1. Coprimary efficacy measure: PLP and PPi
Median changes from Baseline to Month 6 in plasma concentrations
of PLP (Fig. 3a) and PPi (Fig. 3b) were greater in the combined asfotase
alfa group (n=13) compared with the control group (n=6). The
difference between groups was statistically significant for changes in
plasma PLP (P=0.0285) but not for changes in plasma PPi
(P=0.0715). Results were similar between the 2 asfotase alfa dose
groups (0.3 and 0.5 mg/kg/d; data not shown).
After the first 6months, the control group (n= 6) transitioned to
asfotase alfa treatment, with the last assessment before treatment in-
itiation considered as Baseline. When analyzing the within subject data
for all patients who were treated during the extension phase (n=19),
significant (P < 0.05) reductions from Baseline in plasma PLP and PPi
Table 1
Baseline demographics and HPP-specific medical history.a
Total cohortb
(N=19)
Primary treatment period
group assignment
Control group
(n=6)
Treatment groupc
(n= 13)
Demographics
Age at enrollment, y 53 (13, 66) 21 (13, 58) 55 (14, 66)
Adults (age≥ 18 y), n (%) 13 (68) 3 (50) 10 (77)
Adolescents (age 13–<18 y), n (%) 6 (32) 3 (50) 3 (23)
Age at HPP sign/symptom onset, y 2.0 (0, 36) 0.9 (0.2, 4) 2.0 (0, 36)
Adults (age≥ 18 y) 3.0 (0.1, 36) 3.0 (0.8, 4) 2.5 (0.1, 36)
Adolescents (age 13–<18 y) 0.3 (0, 1) 0.5 (0.2, 1) 0.2 (0, 0.5)
≥18 y, n (%) 1 (5) 0 (0) 1 (8)
< 18 y, n (%) 18 (95) 6 (100) 12 (92)
Female, n (%) 12 (63) 2 (33) 10 (77)
Race, white, n (%) 18 (95) 5 (83) 13 (100)
HPP-specific medical history
Baseline serum ALP, U/Ld 18.0 (18, 45) 23.5 (18, 45) 18.0 (18, 35)
Baseline plasma PLP, ng/mLe 267.0 (29, 1590) 237.0 (106, 906) 267.0 (29, 1590)
Baseline plasma PPi, μMf 5.2 (2.2, 12.1) 6.2 (4.2, 12.1) 5.1 (2.2, 8.2)
Patients with fractures, n (%) 18 (95) 6 (100) 12 (92)
Pseudofractures, n (%) 12 (63) 5 (83) 7 (54)
Nonhealing fractures, n (%) 6 (32) 1 (17) 5 (39)
Number of fractures 6 (1, 30) 5 (1, 8) 9.5 (1, 30)
Bone pain severity, n (%)
Limits activity 18 (95) 5 (83) 13 (100)
Requires analgesics 16 (84) 5 (83) 11 (85)
Muscle complaints, n (%)
Weakness 17 (90) 5 (83) 12 (92)
Pain 14 (74) 4 (67) 10 (77)
Joint complaints, n (%)
Pain 17 (90) 5 (83) 12 (92)
Swelling 7 (37) 2 (33) 5 (39)
Unusual gait or walk/run, n (%) 15 (79) 4 (67) 11 (85)
Assistive devices (≥1) used at Screening, n (%) 12 (63) 4 (67) 8 (62)
Craniosynostosis, n (%) 3 (16) 0 3 (23)
Premature loss of deciduous teeth, n (%) 16 (84) 5 (83) 11 (85)
Loss of adult teeth, n (%) 8 (42) 1 (17) 7 (54)
Number of adult teeth remaining 24 (0, 30) 26 (0, 28) 23 (0, 30)
Hypercalcemia, n (%) 6 (32) 3 (50) 3 (23)
Hyperphosphatemia, n (%) 6 (32) 2 (33) 4 (31)
Gout, n (%) 5 (26) 2 (33) 3 (23)
Kidney stones,g n (%) 4 (21) 2 (33) 2 (15)
ALP= alkaline phosphatase; HPP=hypophosphatasia; PLP= pyridoxal 5′-phosphate; PPi= inorganic pyrophosphate.
a Values presented medians (min, max) unless noted otherwise.
b Combined because all patients were treated in the extension phase.
c Asfotase alfa groups combined for analysis.
d Normal ALP ranges by age and sex per Covance, Inc.: males 10–<15 years (95–385 U/L), 15–<18 years (50–250 U/L), 18–< 50 years
(31–129 UL), 50–<60 years (35–131 U/L), and 60–< 70 years (35–125 U/L); females 10–< 15 years (51–300 U/L), 15–<18 years (31–110 U/L),
18–<50 years (31–106 U/L), and 50–< 70 years (35–123 U/L).
e Normal PLP ranges by age category per Biotrial Bioanalytical Services: 5–18 years (5.7–61.2 ng/mL) and>18 years (2.8–26.7 ng/mL).
f Normal PPi ranges by age category per Charles River Laboratories: 13–18 years (< 0.8–4.8 μM) and> 18 years (1.0–5.8 μM).
g As reported in the patient's medical history.
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concentrations were observed at 6months of treatment and maintained
through 5 years (Fig. 4).
Planned subgroup analyses based on patient age showed that the
adults (≥18 years of age) had significant reductions in plasma con-
centrations of PLP (P=0.049) and PPi (P=0.028) from Baseline to
Month 6 in the combined asfotase alfa group (n=10) versus the con-
trol group (n=3). In adolescents (13–16 years of age), reductions in
plasma PLP and PPi from Baseline to Month 6 were not significant
(P > 0.05) between the combined asfotase alfa group (n=3) and the
control group (n=3).
3.2.2. Secondary efficacy measures
3.2.2.1. Bone mineralization: transiliac bone biopsy. Bone
histomorphometry was performed at Baseline and Year 1 in the
asfotase alfa group and at Baseline and Month 6 in the control group.
Our assessment (Shriners Hospital for Children, Montreal, Quebec,
Canada) showed the Baseline mean (SD) osteoid volume per bone
volume was 6.5% (3.9) in the combined asfotase alfa group (n= 13)
and 11.6% (4.5) in the control group (n= 6). Mean osteoid volume per
bone volume decreased at Year 1 in the asfotase alfa group (mean [SD]
change from Baseline: −0.8% [3.4]; n= 12) and increased at Month 6
in the control group (+0.2% [4.8]; n= 6).
For comparison with the healthy population, the data were analyzed
as % of healthy mean (described in Methods), with a score of 100%
indicating no difference from the healthy population. Baseline mean
(SD) % of healthy mean osteoid volume per bone volume was 386.1%
(238.8) in the combined asfotase alfa group and 548.7% (215.3) in the
control group; mean (95% CI) changes from Baseline for either of these
groups (combined asfotase alfa: −103.1% [−310.0, 103.9]; control:
−10.8% [−353.8, 332.2]) were not statistically significant. Baseline
mean (SD) % of healthy mean osteoid thickness was 108.9% (35.4) in
the combined asfotase alfa group and 178.5% (57.2) in the control
group; mean (95% CI) changes from Baseline for either of these groups
(combined asfotase alfa group: −0.5% [−39.3, 38.4]; control: −11.4%
[−136.2, 113.4]) were not statistically significant. Baseline mean (SD)
% of healthy mean mineralization lag time was 891% (623) in the
combined asfotase alfa group and 530% (192) in the control group.
Percent of healthy mean mineralization lag time decreased from
Baseline to Year 1 by a mean (95% CI) of −580% (−101, −452) in the
asfotase alfa group, which represents a significant change (P < 0.05),
and increased from Baseline to Month 6 by 349% (−590, 1288) in the
control group, which was not a statistically significant change.
3.2.2.2. Bone mineral density: DXA. In the 6-month primary treatment
period, no statistically significant differences between treated and
control patients were observed in mean (SD) changes from Baseline
for the BMD Z-scores for the lumbar spine (combined asfotase alfa:
+0.2 [0.2]; control: −0.02 [0.3]), total hip (combined asfotase alfa:
+0.1 [0.1]; control: +0.3 [0.2]), or whole body (combined asfotase
alfa: −0.1 [0.2]; control: +0.2 [0.6]). When data from the primary
treatment period and the extension phase were combined, mean lumbar
spine, total hip, and whole body Z-scores were within the normal range
at Baseline. Significant (P < 0.05) changes from Baseline were
observed at various time points over 5 years of treatment; however,
BMD Z-scores remained within the normal range for the most part and
did not change over time (Fig. 5). In patients older than 50 years of age
(2 men and 8 women), mean T-scores for the lumbar spine, total hip,
and whole body assessments were normal at Baseline (range: +1.1 to
+3.2) and through up to 5 years of treatment (range at 5 years: −0.1 to
+1.7).
3.2.2.3. Walking ability: 6MWT. All randomized patients attempted the
6MWT at Baseline. In the 6-month primary treatment period, only 4 of
6 control patients had Baseline and Month 6 assessments compared
with all 13 asfotase alfa–treated patients (1 control patient had no post-
Baseline assessments because of cognitive impairment and limited
mobility, and 1 did not have a Month 6 assessment because he was
recovering from a motor vehicle accident). The median (min, max)
distance walked during the 6MWT was greater by 35 (−2, 182) meters
in the treated group (n=13) and decreased by 7 (−46, 113) meters in
the control group (n=4) at Month 6. The between-group difference
was not statistically significant (P=0.13).
When data from the primary treatment period and the extension
phase were combined, the median distance walked increased from 355
(10, 620; n=19) meters before initiating treatment to 450 (280, 707;
n=13) meters at 5 years of treatment (Fig. 6a). The increase from
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Fig. 4. Median (a) plasma PLP concentrations and (b) plasma PPi concentrations spanning 5 years of asfotase alfa treatment. Data from the primary treatment period
and extension phase are combined. Of 18 asfotase alfa dose increases, 14 occurred approximately at or after 1 year of treatment with asfotase alfa.
aTime points are from the start of treatment with asfotase alfa. The control group began treatment 6months after the treated group. Baseline for all analyses was the
last assessment before the first dose of asfotase alfa.
*P < 0.05 (95% CI for mean change from Baseline did not include 0).
PLP= pyridoxal 5′-phosphate; PPi= inorganic pyrophosphate.
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Baseline was statistically significant at Month 6 and Years 1, 2, and 3
(P < 0.05; Fig. 6a). Distance walked varied widely among patients
(Supplemental Fig. 1).
The median % predicted distance walked was below normal
(< 84%) at Baseline (76%; n=15), but improved to within the normal
range by 6months of treatment (85%; n=16) and was sustained at
88% (n= 11) at 5 years of treatment in the combined asfotase alfa
group (Fig. 6b). The increase from Baseline was statistically significant
(P < 0.05) at Month 6 and Years 1, 2, 3, 4, and 5 (Fig. 6b).
Use of assistive ambulatory devices was reported in the in-
vestigator's notes for 5 of the 19 patients who attempted the 6MWT at
Baseline (2 in the control group, 2 in the asfotase alfa 0.3mg/kg/d
group, and 1 in the asfotase alfa 0.5 mg/kg/d group). One patient in-
itially in the control group was able with treatment to transition from a
wheelchair to intermittent reliance on crutches by the assessments at
Year 1 and Year 1.5 but was not able to perform the assessment at Year
4 because of pain. A second patient initially in the control group used a
wheeled walker through Year 1.5 and with treatment did not require its
use at both Year 2 and Year 2.5, but compliance with study procedures
was poor and at both visits the assessment was not completed for the
full duration. Three patients maintained a reduction in reliance on as-
sistive devices: 1 patient in the 0.3 mg group used a cane for the first
2 years, and no further use was reported through the last assessment at
Year 4.5; 1 patient in the 0.3mg group used a cane at Baseline, and no
further use of a cane was reported from Month 3 through the last as-
sessment at Year 5.5; and 1 patient in the 0.5 mg group improved from
use of a wheeled walker to intermittent reliance on a cane from Year 2
through the last assessment at Year 6.
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Fig. 5. DXA mean (a) lumbar spine, (b) total hip, and (c) whole body Z-scores spanning 5 years of asfotase alfa treatment. Data from primary treatment period and
extension phase are combined. Of 18 asfotase alfa dose increases, 14 occurred approximately at or after 1 year of treatment.
aTime points are from the start of treatment with asfotase alfa. The control group began treatment 6months after the treated group. Baseline for all analyses was the
last assessment before the first dose of asfotase alfa.
*P < 0.05 (95% CI for mean change from Baseline did not include 0).
BMD=bone mineral density.
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Fig. 6. Median (a) distance walked and (b) % predicted distance walked during the 6MWT spanning 5 years of asfotase alfa treatment. Data from primary treatment
period and extension phase are combined. Of 18 asfotase alfa dose increases, 14 occurred approximately at or after 1 year of treatment. The % predicted was
calculated only if the patient walked the full 6 minutes. Three patients initially assigned to the control group were not included in the % predicted analysis because
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aTime points are from the start of treatment with asfotase alfa. The control group began treatment 6months after the treated group. Baseline for all analyses was the
last assessment before the first dose of asfotase alfa.
*P < 0.05 (95% CI for mean change from baseline did not include 0).
6MWT=6-Minute Walk Test.
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3.2.3. Exploratory efficacy measures
3.2.3.1. Gross motor function: BOT-2. From Baseline to Month 6
concluding the primary treatment period, median total (min, max)
scores on the BOT-2 Running Speed and Agility subtest increased by 4
points (−1, 12) in the combined asfotase alfa group (n= 11),
indicating better performance, and decreased by 0.5 points (−1, 0) in
the control group (n=2). The median total scores on the Strength
subtest increased by 3 points (−2, 8) in the asfotase alfa group and by 4
Fig. 7. Median change from Baseline in
BOT-2 scores for Running Speed and Agility
and Strength subtests (a), median % of
predicted HHD values for hip abduction and
hip extension (b), and median change from
Baseline in LEFS scores (c) spanning 5 years
of asfotase alfa treatment. Data from pri-
mary treatment period and extension phase
are combined. Changes from Baseline in the
BOT-2, HHD and LEFS measures were not
subject to hypothesis testing because these
were exploratory efficacy measures. Of 18
asfotase alfa dose increases, 14 occurred
approximately at or after 1 year of treat-
ment.
aTime points are from the start of treatment
with asfotase alfa. The control group began
treatment 6months after the treated group.
Baseline for all analyses was the last as-
sessment before the first dose of asfotase
alfa.
BOT-2=Bruininks-Oseretsky Test of Motor
Proficiency, second edition; HHD=
handheld dynamometry; LEFS= Lower
Extremity Functional Scale.
P.S. Kishnani, et al. Bone 121 (2019) 149–162
158
points (1, 7) in the control group. After 5 years of treatment with
asfotase alfa, the median changes from Baseline were 4 points in total
Running Speed and Agility score (n= 11) and 3.5 points in total
Strength score (n= 12), indicating improvement (Fig. 7a).
3.2.3.2. Muscle strength: HHD. Some improved strength in the proximal
muscles of the hip was observed with treatment (Fig. 7b). After 5 years
of treatment, median changes from Baseline in % predicted hip
extension and hip abduction were 12.4 (n=9) and 9.8 (n=11),
respectively.
3.2.3.3. Patient-reported functional disability: LEFS. In the 6-month
primary treatment period, clinically meaningful improvements in
LEFS scores (≥9-point increase) were observed for 4 of 13 (31%)
patients in the asfotase alfa group and for 1 of 5 (20%) in the control
group.
Over the extension phase, 14 of 18 patients (78%) with Baseline
data had increases (i.e., improved) in LEFS scores at the last assessment,
whereas 4 (22%) had either no change or decreased scores. For 7 of
these 18 (39%) patients, the changes represented clinically meaningful
improvements at the last assessment (Fig. 7c).
3.2.4. Patient-reported pain: BPI-SF
At Baseline, the median (min, max) BPI-SF total pain severity score
was 15.0 (0, 30) in the combined asfotase alfa group (n= 13) and 12.0
(5, 25) in the control group (n=6). In the primary treatment period,
changes from Baseline to Month 6 were similar between the treated
(−2.0 [−17, 4]; n= 13) and control groups (−3.0 [−11, 1]; n= 4).
BPI-SF scores improved over the extension period, with a median (min,
max) decline from Baseline of −1.0 (−21, 8; n= 19) at Year 1 and
−3.5 (−20, 5; n= 16) after up to 5 years of treatment.
3.3. Safety
No deaths occurred during the study. All patients experienced ≥1
treatment-emergent AE (TEAE); most TEAEs were mild (864/1145
[75%]) or moderate (229/1145 [20%]) in intensity. Table 2 sum-
marizes the TEAEs reported in>3 patients. The most common TEAEs
were ISRs (385/1145 [34%]), which occurred in all patients. The most
common ISRs (≥5 patients) were erythema (13/19 [68%]), hematoma
(10/19 [53%]), skin discoloration (9/19 [47%]), ISR not otherwise
specified (7/19 [37%]), pain (6/19 [32%]), atrophy (5/19 [26%]), and
pruritus (5/19 [26%]). Two patients experienced TEAEs categorized as
hypersensitivity IARs, oral hypoesthesia and chills in 1 patient and
anaphylactoid reaction in 1 patient (see Supplemental materials); each
was considered moderate in intensity. The patient who had the ana-
phylactoid reaction withdrew from the study. In 1 patient, the dose of
asfotase alfa was reduced (from 0.5mg/kg/d 7 times per week to
0.5 mg/kg/d 3 times per week) because of ISRs (discoloration, atrophy,
and pruritus).
A total of 29 treatment-emergent SAEs were reported for 9 patients.
Eight events in 2 patients were assessed by the investigator as related to
study drug (oral hypoesthesia, chills, pain in extremity, and headache
in 1 patient and hypersensitivity reaction and anaphylactoid reaction in
1 patient).
Eleven patients had 22 events of injection site lipodystrophy, none
of which were SAEs. All of these events were ongoing at the end of the
study except for 3 events in 2 patients (2 events of hypertrophy in both
arms of 1 patient resolved after ~17months and 1 event of stretched
skin at the umbilicus resolved after ~16months).
Two patients had ocular calcifications noted on ophthalmologic/
funduscopic exam at Baseline, which is consistent with the natural
history of HPP. Nine patients (13–66 years of age) had treatment-
emergent ocular calcifications located either at the conjunctiva or
corneal limbus, none of which were considered SAEs. These calcifica-
tions were first observed after ≥72weeks of treatment in all but 2
patients. None of these 9 patients had ocular calcifications noted at
Baseline. All ocular calcifications were considered mild in severity, did
not worsen during the study, and did not affect vision or ocular struc-
ture. Of the 9 patients, 2 underwent conjunctival biopsy that showed
epithelial-subepithelial junction calcification and actinic elastosis
(Supplemental Fig. 2). All these events were considered by the in-
vestigator to be possibly (9 events) or probably (2 events) related to
study drug.
One patient had nephrocalcinosis noted at Baseline, which is con-
sistent with early-onset, severe hypophosphatasia. Two patients (1
adult and 1 adolescent) had 3 TEAEs of nephrocalcinosis identified by
renal ultrasound, as assessed routinely by the study site radiologist(s),
after 22 weeks of treatment or longer. Neither of these patients had
renal calcification on the Baseline ultrasound. The investigators con-
sidered all events to be mild in severity; 1 event was considered pos-
sibly related to study drug, and 2 were considered unlikely related or
unrelated to study drug.
Eleven patients had a total of 25 fractures reported as TEAEs; none
were considered related to treatment.
Laboratory assessments of serum ALP activity for the entire treated
cohort showed that, as expected, ALP activity was markedly increased
with asfotase alfa treatment (Supplemental Fig. 3). Median ALP activity
peaked at 6819 U/L (range: 3047–12,630; n=13) at 4 years after the
dose was increased to 6mg/kg/wk. At final assessment (Year 5),
median ALP activity was 3154 U/L (range: 803–9917; n=19).
Seventeen of 19 (89.5%) patients tested positive for anti–asfotase
alfa antibodies. Three patients had peak titers during treatment that
were considered high (> 128), with a maximum titer of 512. No patient
had a high titer at the last assessment. Four of the 17 (23.5%) patients
with positive anti–asfotase alfa antibody results tested positive for
neutralizing antibodies (in vitro assay % inhibition:> 4.5%) during
treatment (range: 4.6% to 5.9%), but none tested positive for neu-
tralizing antibodies at the last assessment.
4. Discussion
This Phase 2, dose-ranging study is the first to assess the efficacy and
safety of asfotase alfa initiated in adults and adolescents with HPP, nearly
all of whom had the infantile or childhood forms of HPP. The coprimary
efficacy measure of change in plasma PLP concentration was met, with
significant decreases in plasma PLP observed in treated versus control
patients at Month 6. However, statistical significance of the coprimary
efficacy measure of change in PPi concentration during the 6-month
primary treatment period was not met. Notably, the dose of asfotase alfa
(2.1–3.5mg/kg/wk) administered during the 6-month primary treatment
period, and initially in the open-label extension phase, was lower than
the dose administered in later investigations of asfotase alfa in perinatal,
infantile, and childhood forms of HPP (6mg/kg/wk) [41,42]. For most
patients in the current study, asfotase alfa reduced plasma concentrations
of PLP and PPi to within the normal range, maintaining normal substrate
concentrations through study end, consistent with its expected biologic
action [24] and previous studies in infants and children with HPP
[25,27]. Circulating levels of these substrates typically remained within
the normal range despite high ALP activity when patients were receiving
asfotase alfa treatment (Supplemental Fig. 3). Pharmacodynamic results
in the primary treatment period were similar in the 2 asfotase alfa dose
groups (0.3 and 0.5mg/kg/d).
Importantly, the decreases in circulating TNSALP substrates were
associated with improved functional measures in treated patients at the
end of the 6-month primary treatment period. In the extension phase, a
protocol amendment allowed the dose to be increased to 6mg/kg/wk,
comparable to the dose showing effectiveness in children [27]. In-
creasing the dose of asfotase alfa was associated with further reductions
in TNSALP substrates and seemed to be associated with additional
improvements in functional measures. TNSALP substrates generally
stayed within the normal range during treatment with the higher dose,
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suggesting that it was not excessive.
At Baseline, the adults and adolescents with HPP enrolled in this
study had elevations in osteoid volume per bone volume and miner-
alization lag time, consistent with the impaired skeletal mineralization of
this disorder [21]. Baseline values of osteoid thickness were more vari-
able, with higher values in the control group than the combined asfotase
alfa group. The only significant change from Baseline was observed for
mineralization lag time in the treated group at Year 1. Interpretation of
these biopsy data was, however, perhaps limited by the study design as
biopsy results from the previous Phase 1 investigation were used as
Baseline values for some patients, resulting in variability in the time
between biopsies. Furthermore, biopsies were conducted after treatment
with low-dose asfotase alfa (2.1–3.5mg/kg/wk), not after the dose was
increased to 6mg/kg/wk.
There were no clear differences between treated and control pa-
tients in DXA results at the end of the 6-month primary treatment
period. When data from the primary treatment period and extension
phase were combined, mean lumbar spine and total hip BMD Z-scores
were within normal range at Baseline; the mean values for whole body
BMD were somewhat elevated early on and then fell into the normal
range [31]. Although treated patients showed changes from Baseline in
lumbar spine, total hip, and whole body BMD Z-scores that persisted
through the extension phase, mean scores remained mostly within the
normal range, with no suggestion of excessive mineralization with
treatment. In clinical practice, Z-scores are generally recommended for
women prior to menopause and in men younger than 50 years of age
[31]. In our patients older than 50 years of age, mean T-scores were
normal at Baseline and through up to 5 years of treatment.
Normal or above normal DXA BMD measurements in HPP patients
have been noted by other investigators as well [43,44]. The explanation
is unclear, but it has been postulated that increased bone tissue from
osteomalacia or distorted bone trabeculation with areas of decreased
mineralization and areas of local hypermineralization (sclerosis) may
impact DXA results in HPP patients [45]. As such, DXA BMD mea-
surements may be confusing for the assessment of disease severity and
treatment response in patients with HPP.
Patients with HPP often have poor strength and compromised
physical function that can manifest as decreased ambulatory ability
among other functional problems [14,16,17]. In the web-based Hypo-
phosphatasia Impact Patient Survey (HIPS) and the Hypophosphatasia
Outcomes Study Telephone interview (HOST) of 125 adults with HPP,
60% reported use of an ambulatory assistive device at some time (e.g.,
wheelchairs, walkers, canes, orthotics) [14]. In the current study, pa-
tients had a wide spectrum of functional capabilities at Baseline, ran-
ging from normal ambulation to nonambulatory. Although considerable
variability of response concerning functional measures was demon-
strated among the treated patients, several of them experienced clini-
cally meaningful improvements in mobility. As detailed in Supple-
mental Fig. 1, of the 18 patients with a Baseline and post-Baseline
assessment, 14 (78%) improved in distance walked. The % predicted
distance walked on the 6MWT for the entire treatment group improved
from below normal (< 84%) to within the normal range for healthy
peers at Month 6, and was sustained through Year 5. Median changes in
distance walked at Years 1, 2, 3, 4, and 5 (range: 49–83m) exceeded the
MCID for adults and adolescents with pediatric-onset HPP of 31m and
43m, respectively [35]. Further, although information concerning use
of ambulatory devices was not formally collected in the study, in-
vestigator notes indicated that 5 patients used assistive devices
(wheelchair, walker, crutches, or cane) while attempting the 6MWT at
Baseline. At study end, 2 patients no longer relied on assistive devices
and 1 patient improved from reliance on a walker to use of a cane.
Improvements were also recorded for some patients in gross motor
function (BOT-2 scores), proximal muscle strength (HHD assessments),
and patient-reported functional disability (LEFS scores). Improved
mobility might enable some patients to engage in new activities,
leading to accidents after prolonged periods of immobilization, and
confounding assessments of functional improvements.
This study has several limitations. The coprimary efficacy measure
(change from Baseline in PLP and PPi at Month 6) was not met, possibly
because of small sample sizes. Furthermore, study patients received lower
doses of asfotase alfa (2.1–3.5mg/kg/wk) during the primary treatment
period and in the beginning of the extension phase than later in the ex-
tension phase. Although no statistical analyses were performed during the
extension phase to assess the effect of increasing the dose to the currently
indicated 6mg/kg/wk, the doses in the primary treatment period were
possibly suboptimal for decreasing the TNSALP substrate concentrations,
shown by the biochemical data (PLP, PPi). A later study assessing the
pharmacodynamics and pharmacokinetics of asfotase alfa in adults with
pediatric-onset HPP demonstrated that the doses of 6 and 9mg/kg/wk
provide significantly greater reductions in PPi than 1.5mg/kg/wk [46],
confirming the efficacy of doses higher than those initially evaluated in
the current study. It should also be noted that, at this time, assays for PPi
are not commercially available. In addition, the study population with
this rare disorder was heterogeneous with interindividual differences that
may have influenced the results, including age at Baseline, age at onset of
signs or symptoms of HPP, and genetic background. There were im-
balances between the control and treatment groups with regard to some
Baseline characteristics such that the control group may have had more
substantial disease burden. All patients in the control group had a medical
history of fracture at Baseline, despite their younger age (median: 21 vs.
55 years in the combined asfotase alfa group); 3/6 were unable to per-
form the 6MWT at Baseline because of physical and/or cognitive im-
pairment, and 5/6 had compound heterozygous ALPL mutations (com-
pared with 5/13 in the combined asfotase alfa group with a single allele
mutation). Lastly, given the small sample size, results of prespecified
subgroup analyses comparing adults with adolescents were inconclusive,
and the low number of adolescents enrolled in the study does not allow
for generalizability of the data to this age group.
Table 2
TEAEs occurring in> 3 patients during the study.
TEAE (preferred term) Patients, n (%)
N=19
Arthralgia 13 (68)
Injection site erythema 13 (68)
Pain in extremity 12 (63)
Back pain 10 (53)
Injection site hematoma 10 (53)
Bone pain 9 (47)
Injection site discoloration 9 (47)
Musculoskeletal pain 8 (42)
Peripheral edema 8 (42)
Dizziness 7 (37)
Eye deposit 7 (37)
Foot fracture 7 (37)
Injection site reaction not otherwise specified 7 (37)
Joint swelling 7 (37)
Upper respiratory tract infection 7 (37)
Headache 6 (32)
Injection site pain 6 (32)
Nasopharyngitis 6 (32)
Cough 5 (26)
Fall 5 (26)
Injection site atrophy 5 (26)
Injection site pruritus 5 (26)
Procedural pain 5 (26)
Sinusitis 5 (26)
Fatigue 4 (21)
Injection site hypertrophy 4 (21)
Injection site swelling 4 (21)
Nausea 4 (21)
Oropharyngeal pain 4 (21)
Osteoarthritis 4 (21)
Paraesthesia 4 (21)
Post-traumatic pain 4 (21)
TEAE= treatment-emergent adverse event.
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As mentioned, although standardized protocols were provided and
surgeons performing bone biopsies had such experience, interpretation
of the bone biopsy and perhaps DXA results (both secondary efficacy
measures) was limited by varying techniques across sites. The study was
also not powered to show differences in secondary or exploratory
measures. Some of the functional outcome scales used may not have
been appropriate for the study population. For example, the BOT-2 is
validated only for ages 4–21 years [36]. Because the median age of
patients with HPP in this study at enrollment was 53 years, only total
scores were used rather than age-standardized scores.
Asfotase alfa was generally well tolerated over 5 years of treatment. No
patient deaths occurred during the study. Two patients had hypersensi-
tivity reactions; the patient who experienced oral hypoesthesia and chill
resumed asfotase alfa therapy without further reactions, and the patient
who had an anaphylactoid reaction withdrew from the study. TEAEs were
generally mild or moderate in intensity and were most commonly ISRs.
The risk of ISRs such as lipohypertrophy and injection site atrophy can be
reduced by rotating injection sites between the abdominal, deltoid, and
thigh areas [47]. Asymptomatic conjunctival calcifications occurred after
initiating treatment in 9 patients, with no effect on vision or the anatomic
integrity of the eye. Ophthalmologic examinations were not standardized
in this study and some of the exams conducted post-treatment were more
detailed than those conducted at Baseline. Hence, some calcifications may
have been missed at Baseline. It is unclear whether these ectopic calcifi-
cations observed in patients with HPP treated with asfotase alfa are a
consequence of the disease or related to treatment. Anti–asfotase anti-
bodies were detected in 17 patients, 4 of whom transiently tested positive
for neutralizing antibodies during treatment. There was no certain evi-
dence of a clinically relevant effect on efficacy or safety, such as loss of
efficacy, hypersensitivity, or need for dose change, in these 4 patients.
4.1. Conclusions
Consistent with its intended biologic action, asfotase alfa treatment
in adults and adolescents with HPP decreased plasma concentrations of
PLP and PPi to levels within normal reference ranges by Month 6. When
comparing the treatment group and the control group at Month 6, re-
duction in PLP reached statistical significance while the numerical de-
creases in PPi did not. Levels of these ALP substrates were maintained
within the normal range through 5 years of therapy. Treatment with
asfotase alfa was generally well tolerated, with ISRs being the most
common TEAE. Although statistical significance on the prespecified
coprimary efficacy measure (reductions in PLP and PPi at Month 6) was
not met, the totality of the data indicates efficacy of asfotase alfa in the
treatment of this older population of patients with HPP.
Acknowledgments
The authors thank Marisa Gayron, MS, an employee of Alexion
Pharmaceuticals, Inc., at the time of the study, for her contributions to the
statistical analyses, and Katherine L. Madson, PhD, MD, Amy L. Reeves, MS,
CCRP, Karen E. Mack, LPN, and Upasana Nanda, MPH, at Shriners Hospital
for Children, St. Louis, MO, USA for their help studying the patients.
Funding
This study was sponsored by Alexion Pharmaceuticals, Inc., Boston,
MA, USA. Editorial support was provided by Lela Creutz, PhD, and Bina
J. Patel, PharmD, CMPP, of Peloton Advantage, LLC, and was funded by
Alexion Pharmaceuticals, Inc., Boston, MA, USA
Author roles
Study design: Michael P. Whyte; Priya S. Kishnani; Cheryl Rockman-
Greenberg; Scott Moseley; Andrew Denker; Eric Watsky
Study investigator: Priya S. Kishnani; Cheryl Rockman-Greenberg;
Michael P. Whyte
Enrolled patients: Priya S. Kishnani; Cheryl Rockman-Greenberg;
Michael P. Whyte
Collection and assembly of data: Priya S. Kishnani; Cheryl Rockman-
Greenberg; Michael P. Whyte; M. Tariq Bhatti
Data analysis: Scott Moseley; Andrew Denker; Eric Watsky
Data interpretation: All authors
Manuscript review and revisions: All authors
Final approval of manuscript: All authors
Author disclosures
This study was sponsored by Alexion Pharmaceuticals, Inc. Priya S.
Kishnani was a clinical study investigator and received honoraria and
travel support from Alexion Pharmaceuticals, Inc., for consulting and
participation on advisory boards. Cheryl Rockman-Greenberg was a clin-
ical study investigator and received honoraria, travel support, and re-
search grant support from Alexion Pharmaceuticals, Inc., for consulting
and participation on advisory boards. Michael P. Whyte was a clinical
study investigator and received honoraria, travel support, and research
grant support from Alexion Pharmaceuticals, Inc. M. Tariq Bhatti was a
clinical study investigator and received consultancy fees from Alexion
Pharmaceuticals, Inc. Frank Rauch received consultancy fees from Alexion
Pharmaceuticals, Inc. Scott Moseley and Andrew E. Denker are employees
of Alexion Pharmaceuticals, Inc., the study sponsor, and may own stock
options in the company. At the time of the study, Eric Watsky was an
employee of and may own stock/options in Alexion Pharmaceuticals, Inc.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.bone.2018.12.011.
References
[1] M.P. Whyte, Hypophosphatasia: an overview for 2017, Bone 102 (2017) 15–25,
https://doi.org/10.1016/j.bone.2017.02.011.
[2] M.J. Weiss, D.E. Cole, K. Ray, M.P. Whyte, M.A. Lafferty, R.A. Mulivor, H. Harris, A
missense mutation in the human liver/bone/kidney alkaline phosphatase gene
causing a lethal form of hypophosphatasia, Proc. Natl. Acad. Sci. U. S. A. 85 (20)
(1988) 7666–7669.
[3] A. Taillandier, C. Domingues, A. Dufour, F. Debiais, P. Guggenbuhl, C. Roux,
C. Cormier, B. Cortet, V. Porquet-Bordes, F. Coury, D. Genevieve, J. Chiesa, T. Colin,
E. Fletcher, A. Guichet, R.M. Javier, M. Laroche, M. Laurent, E. Lausch, B. LeHeup,
C. Lukas, G. Schwabe, I. van der Burgt, C. Muti, B. Simon-Bouy, E. Mornet, Genetic
analysis of adults heterozygous for ALPL mutations, J. Bone Miner. Metab. 36 (6)
(2018) 723–733, https://doi.org/10.1007/s00774-017-0888-6.
[4] E. Mornet, The tissue nonspecific alkaline phosphatase gene mutations database, http://
www.sesep.uvsq.fr/03_hypo_mutations.php, (2018) , Accessed date: 1 July 2018.
[5] P.S. Henthorn, M. Raducha, K.N. Fedde, M.A. Lafferty, M.P. Whyte, Different mis-
sense mutations at the tissue-nonspecific alkaline phosphatase gene locus in auto-
somal recessively inherited forms of mild and severe hypophosphatasia, Proc. Natl.
Acad. Sci. U. S. A. 89 (20) (1992) 9924–9928.
[6] S. Baumgartner-Sigl, E. Haberlandt, S. Mumm, S. Scholl-Burgi, C. Sergi, L. Ryan,
K.L. Ericson, M.P. Whyte, W. Hogler, Pyridoxine-responsive seizures as the first symptom
of infantile hypophosphatasia caused by two novel missense mutations (c.677T > C,
p.M226T; c.1112C > T, p.T371I) of the tissue-nonspecific alkaline phosphatase gene,
Bone 40 (6) (2007) 1655–1661, https://doi.org/10.1016/j.bone.2007.01.020.
[7] M.P. Whyte, J.D. Mahuren, L.A. Vrabel, S.P. Coburn, Markedly increased circulating
pyridoxal-5′-phosphate levels in hypophosphatasia. Alkaline phosphatase acts in
vitamin B6 metabolism, J. Clin. Invest. 76 (2) (1985) 752–756, https://doi.org/10.
1172/jci112031.
[8] H. Fleisch, R.G. Russell, F. Straumann, Effect of pyrophosphate on hydroxyapatite
and its implications in calcium homeostasis, Nature 212 (5065) (1966) 901–903.
[9] R.G. Russell, Excretion of inorganic pyrophosphate in hypophosphatasia, Lancet 2
(7410) (1965) 461–464.
[10] M.P. Whyte, Physiological role of alkaline phosphatase explored in hypopho-
sphatasia, Ann. N. Y. Acad. Sci. 1192 (2010) 190–200, https://doi.org/10.1111/j.
1749-6632.2010.05387.x.
[11] M.P. Whyte, Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and
treatment, Nat. Rev. Endocrinol. 12 (4) (2016) 233–246, https://doi.org/10.1038/
nrendo.2016.14.
[12] A. Linglart, M. Biosse-Duplan, Hypophosphatasia, Curr. Osteoporos. Rep. 14 (3)
(2016) 95–105, https://doi.org/10.1007/s11914-016-0309-0.
[13] N. Bishop, Clinical management of hypophosphatasia, Clin. Cases Miner. Bone
P.S. Kishnani, et al. Bone 121 (2019) 149–162
161
Metab. 12 (2) (2015) 170–173, https://doi.org/10.11138/ccmbm/2015.12.2.170.
[14] T.J. Weber, E.K. Sawyer, S. Moseley, T. Odrljin, P.S. Kishnani, Burden of disease in
adult patients with hypophosphatasia: results from two patient-reported surveys,
Metabolism 65 (2016) 1522–1530.
[15] M.P. Whyte, Hypophosphatasia and how alkaline phosphatase promotes miner-
alization, in: R.V. Thakker, M.P. Whyte, J. Eisman, T. Igarashi (Eds.), Genetics of
Bone Biology and Skeletal Disease, Elsevier (Academic Press), San Diego, CA, 2018,
pp. 481–504.
[16] K.E. Berkseth, P.J. Tebben, M.T. Drake, T.E. Hefferan, D.E. Jewison, R.A. Wermers,
Clinical spectrum of hypophosphatasia diagnosed in adults, Bone 54 (1) (2013)
21–27, https://doi.org/10.1016/j.bone.2013.01.024.
[17] J.D. Coe, W.A. Murphy, M.P. Whyte, Management of femoral fractures and pseudo-
fractures in adult hypophosphatasia, J. Bone Joint Surg. Am. 68 (7) (1986) 981–990.
[18] A.J. Chuck, M.G. Pattrick, E. Hamilton, R. Wilson, M. Doherty, Crystal deposition in
hypophosphatasia: a reappraisal, Ann. Rheum. Dis. 48 (7) (1989) 571–576.
[19] A.W. Eade, A.J. Swannell, N. Williamson, Pyrophosphate arthropathy in hypo-
phosphatasia, Ann. Rheum. Dis. 40 (2) (1981) 164–170.
[20] T. Taketani, K. Onigata, H. Kobayashi, Y. Mushimoto, S. Fukuda, S. Yamaguchi,
Clinical and genetic aspects of hypophosphatasia in Japanese patients, Arch. Dis.
Child. 99 (3) (2014) 211–215, https://doi.org/10.1136/archdischild-2013-305037.
[21] F. Barvencik, F.T. Beil, M. Gebauer, B. Busse, T. Koehne, S. Seitz, J. Zustin,
P. Pogoda, T. Schinke, M. Amling, Skeletal mineralization defects in adult hypo-
phosphatasia—a clinical and histological analysis, Osteoporos. Int. 22 (10) (2011)
2667–2675, https://doi.org/10.1007/s00198-011-1528-y.
[22] A. Reibel, M.C. Maniere, F. Clauss, D. Droz, Y. Alembik, E. Mornet, A. Bloch-Zupan,
Orodental phenotype and genotype findings in all subtypes of hypophosphatasia,
Orphanet J. Rare Dis. 4 (2009) 6, https://doi.org/10.1186/1750-1172-4-6.
[23] N. Guanabens, S. Mumm, I. Moller, E. Gonzalez-Roca, P. Peris, J.L. Demertzis,
M.P. Whyte, Calcific periarthritis as the only clinical manifestation of hypopho-
sphatasia in middle-aged sisters, J. Bone Miner. Res. 29 (4) (2014) 929–934,
https://doi.org/10.1002/jbmr.2110.
[24] J.L. Millan, S. Narisawa, I. Lemire, T.P. Loisel, G. Boileau, P. Leonard,
S. Gramatikova, R. Terkeltaub, N.P. Camacho, M.D. McKee, P. Crine, M.P. Whyte,
Enzyme replacement therapy for murine hypophosphatasia, J. Bone Miner. Res. 23
(6) (2008) 777–787, https://doi.org/10.1359/jbmr.071213.
[25] M.P. Whyte, C.R. Greenberg, N.J. Salman, M.B. Bober, W.H. McAlister, D. Wenkert,
B.J. Van Sickle, J.H. Simmons, T.S. Edgar, M.L. Bauer, M.A. Hamdan, N. Bishop,
R.E. Lutz, M. McGinn, S. Craig, J.N. Moore, J.W. Taylor, R.H. Cleveland,
W.R. Cranley, R. Lim, T.D. Thacher, J.E. Mayhew, M. Downs, J.L. Millan,
A.M. Skrinar, P. Crine, H. Landy, Enzyme-replacement therapy in life-threatening
hypophosphatasia [with supplementary appendix], N. Engl. J. Med. 1366 (10)
(2012) 904–913, https://doi.org/10.1056/NEJMoa1106173.
[26] M.P. Whyte, C. Rockman-Greenberg, K. Ozono, R. Riese, S. Moseley, A. Melian,
D.D. Thompson, N. Bishop, C. Hofmann, Asfotase alfa treatment improves survival
for perinatal and infantile hypophosphatasia, J. Clin. Endocrinol. Metab. 101 (1)
(2016) 334–342, https://doi.org/10.1210/jc.2015-3462.
[27] M.P. Whyte, K.L. Madson, D. Phillips, A. Reeves, W.H. McAlister, A. Yakimoski,
K.E. Mack, K. Hamilton, K. Kagan, K.P. Fujita, D.D. Thompson, S. Moseley,
T. Odrljin, C. Rockman-Greenberg, Asfotase alfa therapy for children with hypo-
phosphatasia [with on-line only supplement], JCI Insight 1 (9) (2016) e85971.
[28] M.P. Whyte, J.H. Simmons, S. Moseley, K.P. Fujita, N. Bishop, N.J. Salman,
J. Taylor, D. Phillips, M. McGinn, W.H. McAlister, Hypophosphatasia: seven-year
outcomes for life-threatening disease in infants and young children treated with
asfotase alfa, Lancet Diabetes Endocrinol. (2018), https://doi.org/10.1016/S2213-
8587(18)30307-3 (Epub ahead of print).
[29] F.H. Glorieux, R. Travers, A. Taylor, J.R. Bowen, F. Rauch, M. Norman, A.M. Parfitt,
Normative data for iliac bone histomorphometry in growing children, Bone 26 (2)
(2000) 103–109.
[30] R.R. Recker, D.B. Kimmel, A.M. Parfitt, K.M. Davies, N. Keshawarz, S. Hinders,
Static and tetracycline-based bone histomorphometric data from 34 normal post-
menopausal females, J. Bone Miner. Res. 3 (2) (1988) 133–144, https://doi.org/10.
1002/jbmr.5650030203.
[31] International Society for Clinical Densitometry, https://www.iscd.org/official-
positions/official-positions, (2012) , Accessed date: 16 May 2018.
[32] ATS statement, Guidelines for the six-minute walk test, Am. J. Respir. Crit. Care
Med. 166 (1) (2002) 111–117, https://doi.org/10.1164/ajrccm.166.1.at1102.
[33] W.J. Gibbons, N. Fruchter, S. Sloan, R.D. Levy, Reference values for a multiple
repetition 6-minute walk test in healthy adults older than 20 years, J. Cardiopulm.
Rehabil. 21 (2) (2001) 87–93.
[34] R. Geiger, A. Strasak, B. Treml, K. Gasser, A. Kleinsasser, V. Fischer, H. Geiger,
A. Loeckinger, J.I. Stein, Six-minute walk test in children and adolescents, J.
Pediatr. 150 (4) (2007) 395–399, https://doi.org/10.1016/j.jpeds.2006.12.052.
[35] D. Phillips, I.C. Tomazos, S. Moseley, G. L'Italien, S. Lerma Lara, Reliability of the 6-
minute walk test in children, adolescents, and adults with hypophosphatasia [ab-
stract P-OTHD-44], Calcif. Tissue Int. 100 (2017) S148–S149.
[36] J.C. Deitz, D. Kartin, K. Kopp, Review of the Bruininks-Oseretsky test of motor pro-
ficiency, second edition (BOT-2), Phys. Occup. Ther. Pediatr. 27 (4) (2007) 87–102.
[37] K. Thorborg, J. Petersen, S.P. Magnusson, P. Holmich, Clinical assessment of hip
strength using a hand-held dynamometer is reliable, Scand. J. Med. Sci. Sports 20
(3) (2010) 493–501, https://doi.org/10.1111/j.1600-0838.2009.00958.x.
[38] J.M. Binkley, P.W. Stratford, S.A. Lott, D.L. Riddle, The Lower Extremity Functional
Scale (LEFS): scale development, measurement properties, and clinical application.
North American Orthopaedic Rehabilitation Research Network, Phys. Ther. 79 (4)
(1999) 371–383.
[39] C.S. Cleeland, K.M. Ryan, Pain assessment: global use of the Brief Pain Inventory,
Ann. Acad. Med. Singap. 23 (2) (1994) 129–138.
[40] C.S. Cleeland, The Brief Pain Inventory User Guide, The University of Texas M. D.
Anderson Cancer Center, Houston, TX, 2009.
[41] Strensiq [Package Insert], Alexion Pharmaceuticals, Inc., Boston, MA, 2018.
[42] Strensiq [Summary of Product Characteristics], Alexion Europe, Rueil-Malmaison,
France, 2018.
[43] F. Genest, L. Seefried, Subtrochanteric and diaphyseal femoral fractures in hypo-
phosphatasia–not atypical at all, Osteoporos. Int. (2018), https://doi.org/10.1007/
s00198-018-4552-3.
[44] M.P. Whyte, D. Wenkert, F. Zhang, Hypophosphatasia: natural history study of 101
affected children investigated at one research center, Bone 93 (2016) 125–138,
https://doi.org/10.1016/j.bone.2016.08.019.
[45] H.J. Girschick, I. Haubitz, O. Hiort, P. Schneider, Long-term follow-up of bone
mineral density in childhood hypophosphatasia, Joint Bone Spine 74 (3) (2007)
263–269, https://doi.org/10.1016/j.jbspin.2006.06.017.
[46] L. Seefried, P.S. Kishnani, S. Moseley, E. Watsky, M.P. Whyte, K. McCrystal Dahir,
Results from a phase 2a, randomized, multicenter, open-label, dose-ranging study of
asfotase alfa in adults with pediatric hypophosphatasia [abstract], Presented at the
Annual Meeting of the Endocrine Society, Chicago, IL, 2018.
[47] P.S. Kishnani, E.T. Rush, P. Arundel, N. Bishop, K. Dahir, W. Fraser, P. Harmatz,
A. Linglart, C.F. Munns, M.E. Nunes, H.M. Saal, L. Seefried, K. Ozono, Monitoring
guidance for patients with hypophosphatasia treated with asfotase alfa, Mol. Genet.
Metab. 122 (1–2) (2017) 4–17, https://doi.org/10.1016/j.ymgme.2017.07.010.
P.S. Kishnani, et al. Bone 121 (2019) 149–162
162
